Literature DB >> 30511110

[S2k guidelines of the PEG on calculated parenteral initial treatment of bacterial diseases in adults : Focussed summary and supplementary information on antibiotic treatment of critically ill patients].

A Brinkmann1, A C Röhr2, O R Frey2, W A Krüger3, T Brenner4, D C Richter4, K-F Bodmann5, M Kresken6,7, B Grabein8.   

Abstract

In January 2018 the recent revision of the S2k guidelines on calculated parenteral initial treatment of bacterial diseases in adults-update 2018 (Editor: Paul Ehrlich Society for Chemotherapy, PEG) was realized. It is a helpful tool for the complex infectious disease setting in an intensive care unit. The present summary of the guidelines focuses on the topics of anti-infective agents, including new substances, pharmacokinetics and pharmacodynamics as well as on microbiology, resistance development and recommendations for calculated drug therapy in septic patients. As in past revisions the recent resistance situation and results of new clinical studies are considered and anti-infective agents are summarized in a table.

Entities:  

Keywords:  Antibiotic therapy; Evidence based medicine; Guidelines; Sepsis; Septic shock

Mesh:

Substances:

Year:  2018        PMID: 30511110     DOI: 10.1007/s00101-018-0512-8

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  50 in total

1.  Anti-infective drugs during continuous hemodialysis - using the bench to learn what to do at the bedside.

Authors:  Anka C Roehr; Otto R Frey; Andreas Koeberer; Thomas Fuchs; Jason A Roberts; Alexander Brinkmann
Journal:  Int J Artif Organs       Date:  2015-01-23       Impact factor: 1.595

Review 2.  [Procalcitonin as a  tool for the assessment of successful therapy of severe sepsis : An analysis using clinical routine data].

Authors:  K F Bodmann; M Schenker; W Heinlein; M H Wilke
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-07-04       Impact factor: 0.840

3.  [Management of Adult Community-acquired Pneumonia and Prevention - Update 2016].

Authors:  S Ewig; G Höffken; W V Kern; G Rohde; H Flick; R Krause; S Ott; T Bauer; K Dalhoff; S Gatermann; M Kolditz; S Krüger; J Lorenz; M Pletz; A de Roux; B Schaaf; T Schaberg; H Schütte; T Welte
Journal:  Pneumologie       Date:  2016-02-29

4.  A hospital-wide intervention replacing ceftriaxone with cefotaxime to reduce rate of healthcare-associated infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in the intensive care unit.

Authors:  Boun Kim Tan; Emmanuel Vivier; Karim Ait Bouziad; Jean-Ralph Zahar; Christian Pommier; Laurence Parmeland; Caroline Pariset; Pauline Misslin; Catherine Haond; Philippe Poirié; Laura Temime; Mounia N Hocine
Journal:  Intensive Care Med       Date:  2018-02-02       Impact factor: 17.440

Review 5.  Treatment Options for Carbapenem- Resistant Gram-Negative Infections.

Authors:  Moritz Fritzenwanker; Can Imirzalioglu; Susanne Herold; Florian M Wagenlehner; Klaus-Peter Zimmer; Trinad Chakraborty
Journal:  Dtsch Arztebl Int       Date:  2018-05-21       Impact factor: 5.594

6.  Systemic inflammatory response syndrome criteria in defining severe sepsis.

Authors:  Kirsi-Maija Kaukonen; Michael Bailey; David Pilcher; D Jamie Cooper; Rinaldo Bellomo
Journal:  N Engl J Med       Date:  2015-03-17       Impact factor: 91.245

7.  Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.

Authors:  David E Ehmann; Haris Jahić; Philip L Ross; Rong-Fang Gu; Jun Hu; Gunther Kern; Grant K Walkup; Stewart L Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

8.  Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.

Authors:  Pamela A Moise; Darren L Culshaw; Annie Wong-Beringer; Joyce Bensman; Kenneth C Lamp; Winter J Smith; Karri Bauer; Debra A Goff; Robert Adamson; Kimberly Leuthner; Michael D Virata; James A McKinnell; Saira B Chaudhry; Romic Eskandarian; Thomas Lodise; Katherine Reyes; Marcus J Zervos
Journal:  Clin Ther       Date:  2015-11-14       Impact factor: 3.393

9.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

Authors:  Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

Review 10.  Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis.

Authors:  Yu-Chung Chuang; Jann-Tay Wang; Hsin-Yi Lin; Shan-Chwen Chang
Journal:  BMC Infect Dis       Date:  2014-12-13       Impact factor: 3.090

View more
  6 in total

1.  [78-year-old male with disorientation after intestinal resection : Preparation for the medical specialist examination: Part 24].

Authors:  T Schmoch; T Brenner; M A Weigand
Journal:  Anaesthesist       Date:  2019-04       Impact factor: 1.041

2.  [New antibiotics for severe infections due to multidrug-resistant pathogens : Definitive treatment and escalation].

Authors:  D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2019-11       Impact factor: 1.041

3.  Personalized ß-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia: A retrospective analysis on pharmacokinetics and pharmacokinetic target attainment.

Authors:  Ute Chiriac; Otto R Frey; Anka C Roehr; Andreas Koeberer; Patrick Gronau; Thomas Fuchs; Jason A Roberts; Alexander Brinkmann
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

4.  Linezolid use in German acute care hospitals: results from two consecutive national point prevalence surveys.

Authors:  Tobias Siegfried Kramer; Frank Schwab; Michael Behnke; Sonja Hansen; Petra Gastmeier; Seven Johannes Sam Aghdassi
Journal:  Antimicrob Resist Infect Control       Date:  2019-10-21       Impact factor: 4.887

5.  Linezolid Concentrations in Plasma and Subcutaneous Tissue are Reduced in Obese Patients, Resulting in a Higher Risk of Underdosing in Critically Ill Patients: A Controlled Clinical Pharmacokinetic Study.

Authors:  Philipp Simon; David Busse; David Petroff; Christoph Dorn; Lisa Ehmann; Sophie Hochstädt; Felix Girrbach; Arne Dietrich; Markus Zeitlinger; Frieder Kees; Charlotte Kloft; Hermann Wrigge
Journal:  J Clin Med       Date:  2020-04-09       Impact factor: 4.241

6.  Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Reponse Exemplified by Levofloxacin.

Authors:  David Busse; André Schaeftlein; Alexander Solms; Luis Ilia; Robin Michelet; Markus Zeitlinger; Wilhelm Huisinga; Charlotte Kloft
Journal:  Pharm Res       Date:  2021-03-15       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.